3.連結財務諸表及び主な注記
(1)連結貸借対照表
|
|
|
|
|
|
|
|
|
|
|
|
(単位:千円)
|
|
|
|
|
|
|
|
|
|
|
|
前連結会計年度
(2024年12月31日)
|
当連結会計年度
(2025年12月31日)
|
|
資産の部
|
|
|
|
|
流動資産
|
|
|
|
|
|
現金及び預金
|
2,108,484
|
516,789
|
|
|
|
売掛金
|
87,088
|
100,528
|
|
|
|
商品及び製品
|
108,064
|
106,302
|
|
|
|
仕掛品
|
9,069
|
11,609
|
|
|
|
原材料及び貯蔵品
|
37,016
|
36,190
|
|
|
|
前渡金
|
231,819
|
261,308
|
|
|
|
前払費用
|
78,399
|
66,408
|
|
|
|
その他
|
77,774
|
76,389
|
|
|
|
流動資産合計
|
2,737,717
|
1,175,527
|
|
|
固定資産
|
|
|
|
|
|
有形固定資産
|
|
|
|
|
|
|
建物及び構築物(純額)
|
―
|
―
|
|
|
|
|
工具、器具及び備品(純額)
|
―
|
―
|
|
|
|
|
リース資産(純額)
|
―
|
―
|
|
|
|
|
有形固定資産合計
|
―
|
―
|
|
|
|
無形固定資産
|
―
|
―
|
|
|
|
投資その他の資産
|
34,397
|
54,121
|
|
|
|
固定資産合計
|
34,397
|
54,121
|
|
|
資産合計
|
2,772,115
|
1,229,648
|
|
|
|
|
|
|
|
|
|
|
|
|
(単位:千円)
|
|
|
|
|
|
|
|
|
|
|
|
前連結会計年度
(2024年12月31日)
|
当連結会計年度
(2025年12月31日)
|
|
負債の部
|
|
|
|
|
流動負債
|
|
|
|
|
|
買掛金
|
2,000
|
477
|
|
|
|
1年内返済予定の長期借入金
|
19,992
|
8,410
|
|
|
|
リース債務
|
8,112
|
8,491
|
|
|
|
未払金
|
151,733
|
138,665
|
|
|
|
未払法人税等
|
28,526
|
2,079
|
|
|
|
その他
|
12,601
|
9,946
|
|
|
|
流動負債合計
|
222,965
|
168,070
|
|
|
固定負債
|
|
|
|
|
|
転換社債型新株予約権付社債
|
―
|
681,250
|
|
|
|
長期借入金
|
8,410
|
―
|
|
|
|
リース債務
|
24,827
|
16,336
|
|
|
|
資産除去債務
|
39,286
|
54,452
|
|
|
|
その他
|
1,270
|
321
|
|
|
|
固定負債合計
|
73,794
|
752,360
|
|
|
負債合計
|
296,760
|
920,430
|
|
純資産の部
|
|
|
|
|
株主資本
|
|
|
|
|
|
資本金
|
2,447,707
|
14,846
|
|
|
|
資本剰余金
|
6,198,916
|
2,196,625
|
|
|
|
利益剰余金
|
△6,253,962
|
△1,980,588
|
|
|
|
自己株式
|
△222
|
△227
|
|
|
|
株主資本合計
|
2,392,439
|
230,655
|
|
|
その他の包括利益累計額
|
|
|
|
|
|
その他有価証券評価差額金
|
△3,430
|
△2,862
|
|
|
|
為替換算調整勘定
|
86,346
|
81,424
|
|
|
|
その他の包括利益累計額合計
|
82,915
|
78,562
|
|
|
純資産合計
|
2,475,354
|
309,217
|
|
負債純資産合計
|
2,772,115
|
1,229,648
|
E00987
45720
カルナバイオサイエンス株式会社
Carna Biosciences, Inc.
通期第1号参考様式 [日本基準](連結)
Japan GAAP
true
cte
cte
2025-01-01
2025-12-31
FY
2025-12-31
2024-01-01
2024-12-31
2024-12-31
1
false
false
false
45720
2026-02-10
45720
2025-01-01
2025-12-31
45720
2025-01-01
2025-12-31
jppfs_cor:CapitalStockMember
45720
2025-01-01
2025-12-31
jppfs_cor:CapitalSurplusMember
45720
2025-01-01
2025-12-31
jppfs_cor:ForeignCurrencyTranslationAdjustmentMember
45720
2025-01-01
2025-12-31
jpcrp_cor:ReconcilingItemsMember
45720
2025-01-01
2025-12-31
jpcrp_cor:ReportableSegmentsMember
45720
2025-01-01
2025-12-31
jppfs_cor:RetainedEarningsMember
45720
2025-01-01
2025-12-31
jppfs_cor:ShareholdersEquityMember
45720
2025-01-01
2025-12-31
jppfs_cor:TreasuryStockMember
45720
2025-01-01
2025-12-31
tse-acedjpfr-45720:DrugDiscoveryBusinessReportableSegmentsMember
45720
2025-01-01
2025-12-31
tse-acedjpfr-45720:DrugDiscoverySupportBusinessReportableSegmentsMember
45720
2025-01-01
2025-12-31
jppfs_cor:ValuationAndTranslationAdjustmentsMember
45720
2025-01-01
2025-12-31
jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember
45720
2025-12-31
45720
2025-12-31
jppfs_cor:CapitalStockMember
45720
2025-12-31
jppfs_cor:CapitalSurplusMember
45720
2025-12-31
jppfs_cor:ForeignCurrencyTranslationAdjustmentMember
45720
2025-12-31
jpcrp_cor:ReconcilingItemsMember
45720
2025-12-31
jpcrp_cor:ReportableSegmentsMember
45720
2025-12-31
jppfs_cor:RetainedEarningsMember
45720
2025-12-31
jppfs_cor:ShareholdersEquityMember
45720
2025-12-31
jppfs_cor:TreasuryStockMember
45720
2025-12-31
tse-acedjpfr-45720:DrugDiscoveryBusinessReportableSegmentsMember
45720
2025-12-31
tse-acedjpfr-45720:DrugDiscoverySupportBusinessReportableSegmentsMember
45720
2025-12-31
jppfs_cor:ValuationAndTranslationAdjustmentsMember
45720
2025-12-31
jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember
45720
2024-01-01
2024-12-31
45720
2024-01-01
2024-12-31
jppfs_cor:CapitalStockMember
45720
2024-01-01
2024-12-31
jppfs_cor:CapitalSurplusMember
45720
2024-01-01
2024-12-31
jppfs_cor:ForeignCurrencyTranslationAdjustmentMember
45720
2024-01-01
2024-12-31
jpcrp_cor:ReconcilingItemsMember
45720
2024-01-01
2024-12-31
jpcrp_cor:ReportableSegmentsMember
45720
2024-01-01
2024-12-31
jppfs_cor:RetainedEarningsMember
45720
2024-01-01
2024-12-31
jppfs_cor:ShareholdersEquityMember
45720
2024-01-01
2024-12-31
jppfs_cor:TreasuryStockMember
45720
2024-01-01
2024-12-31
tse-acedjpfr-45720:DrugDiscoveryBusinessReportableSegmentsMember
45720
2024-01-01
2024-12-31
tse-acedjpfr-45720:DrugDiscoverySupportBusinessReportableSegmentsMember
45720
2024-01-01
2024-12-31
jppfs_cor:ValuationAndTranslationAdjustmentsMember
45720
2024-01-01
2024-12-31
jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember
45720
2024-12-31
45720
2024-12-31
jppfs_cor:CapitalStockMember
45720
2024-12-31
jppfs_cor:CapitalSurplusMember
45720
2024-12-31
jppfs_cor:ForeignCurrencyTranslationAdjustmentMember
45720
2024-12-31
jpcrp_cor:ReconcilingItemsMember
45720
2024-12-31
jpcrp_cor:ReportableSegmentsMember
45720
2024-12-31
jppfs_cor:RetainedEarningsMember
45720
2024-12-31
jppfs_cor:ShareholdersEquityMember
45720
2024-12-31
jppfs_cor:TreasuryStockMember
45720
2024-12-31
tse-acedjpfr-45720:DrugDiscoveryBusinessReportableSegmentsMember
45720
2024-12-31
tse-acedjpfr-45720:DrugDiscoverySupportBusinessReportableSegmentsMember
45720
2024-12-31
jppfs_cor:ValuationAndTranslationAdjustmentsMember
45720
2024-12-31
jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember
45720
2023-12-31
45720
2023-12-31
jppfs_cor:CapitalStockMember
45720
2023-12-31
jppfs_cor:CapitalSurplusMember
45720
2023-12-31
jppfs_cor:ForeignCurrencyTranslationAdjustmentMember
45720
2023-12-31
jppfs_cor:RetainedEarningsMember
45720
2023-12-31
jppfs_cor:ShareholdersEquityMember
45720
2023-12-31
jppfs_cor:TreasuryStockMember
45720
2023-12-31
jppfs_cor:ValuationAndTranslationAdjustmentsMember
45720
2023-12-31
jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember
iso4217:JPY
xbrli:pure